NASDAQ:AIDX

20/20 Biolabs (AIDX) Stock Price, News & Analysis

20/20 Biolabs logo
$0.16 -0.02 (-13.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.16 +0.01 (+5.03%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About 20/20 Biolabs Stock (NASDAQ:AIDX)

Advanced

Key Stats

Today's Range
$0.16
▼
$0.18
50-Day Range
$0.16
▼
$0.52
52-Week Range
$0.16
▼
$50.00
Volume
301,482 shs
Average Volume
230,171 shs
Market Capitalization
$2.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services.

The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

AI Generated. May Contain Errors.

20/20 Biolabs Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

AIDX MarketRank™: 
1.75855780022 of 5 stars

20/20 Biolabs scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    20/20 Biolabs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    20/20 Biolabs has a consensus price target of $5.00, representing about 3,082.7% upside from its current price of $0.16.

  • Amount of Analyst Coverage

    20/20 Biolabs has only been the subject of 1 research reports in the past 90 days.

  • Read more about 20/20 Biolabs' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 20/20 Biolabs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 20/20 Biolabs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    20/20 Biolabs has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.59% of the float of 20/20 Biolabs has been sold short.
  • Short Interest Ratio / Days to Cover

    20/20 Biolabs has a short interest ratio ("days to cover") of 0.36, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 20/20 Biolabs has recently increased by 405.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    20/20 Biolabs does not currently pay a dividend.

  • Dividend Growth

    20/20 Biolabs does not have a long track record of dividend growth.

  • News Sentiment

    20/20 Biolabs has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for 20/20 Biolabs this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for AIDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 20/20 Biolabs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.66% of the stock of 20/20 Biolabs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    20/20 Biolabs has minimal institutional ownership at this time.

  • Read more about 20/20 Biolabs' insider trading history.
Receive AIDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 20/20 Biolabs and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AIDX Stock News Headlines

Prediction: NVDA will “snap back” on this date
Others paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.tc pixel
20/20 Biolabs Inc (AIDX)
See More Headlines

AIDX Stock Analysis - Frequently Asked Questions

20/20 Biolabs' stock was trading at $3.39 on March 2, 2026. Since then, AIDX shares have decreased by 95.4% and is now trading at $0.1571.

20/20 Biolabs Inc (NASDAQ:AIDX) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business earned $380.22 thousand during the quarter. 20/20 Biolabs had a negative trailing twelve-month return on equity of 539.40% and a negative net margin of 317.83%.

20/20 Biolabs (AIDX) raised $0 in an initial public offering (IPO) on Thursday, February 19th 2026. The company issued 15,164,724 shares at a price of $0.00 per share.

Shares of AIDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:AIDX
CIK
1139685
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+3,082.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.74 million
Net Margins
-317.83%
Pretax Margin
-317.83%
Return on Equity
-539.40%
Return on Assets
-120.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.62
Quick Ratio
1.95

Sales & Book Value

Annual Sales
$2.05 million
Price / Sales
1.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
13,370,000
Free Float
9,670,000
Market Cap
$2.10 million
Optionable
N/A
Beta
N/A
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:AIDX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners